Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).

BMC Cancer · 2020 · PMC7457535 · PMID 32867715

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

a strong trendp = 0.12not close (p > 0.1)

No difference in PFS was found (9.7 months in both arms, HR 1.071; 95%-CI 0.689–1.665, p = 0.76), but a strong trend about enhanced mOS in the experimental arm has been reported (35.7 months vs. 29.8 months; HR: 0.67; 95%-CI 0.41–1.11, p = 0.12) [ 14 ].

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.